Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Neurocrine Biosciences
- Study ID
- NCT05545111
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- NBI-1117568 — DRUGActive treatment with orally administered NBI-1117568
- Placebo — DRUGPlacebo matching NBI-1117568
Study Details
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms.
Key Dates
- Start date
- Oct 4, 2022
- Status verified
- Jul 2025
- Primary completion
- Jul 10, 2024
- Completion
- Jul 10, 2024
Study Design
- Enrollment
- 210 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose Level AParticipant administered Dose Level A (6 weeks)
- Experimental: Dose Level BParticipant administered Dose Level B (6 weeks)
- Experimental: Dose Level CParticipant administered Dose Level C (6 weeks)
- Experimental: Dose Level DParticipant administered Dose Level D (6 weeks)
- Placebo Comparator: Placebo ScheduleParticipant administered placebo (6 weeks)
Primary Outcome Measure
Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score at Week 6 [ Time Frame: Baseline and Week 6 ]
Locations (15)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Neurocrine Clinical Site | Little Rock | Arkansas | 72211 | - |
| Neurocrine Clinical Site | Rogers | Arkansas | 72758 | - |
| Neurocrine Clinical Site | Lemon Grove | California | 91945 | - |
| Neurocrine Clinical Site | Pico Rivera | California | 90660 | - |
| Neurocrine Clinical Site | San Diego | California | 92123 | - |
| Neurocrine Clinical Site | Torrance | California | 90502 | - |
| Neurocrine Clinical Site | Miami Lakes | Florida | 33016 | - |
| Neurocrine Clinical Site | Oakland Park | Florida | 33334 | - |
| Neurocrine Clinical Site | Gaithersburg | Maryland | 20877 | - |
| Neurocrine Clinical site | St Louis | Missouri | 63141 | - |
| Neurocrine Clinical Site | Berlin | New Jersey | 08053 | - |
| Neurocrine Clinical Site | North Canton | Ohio | 44720 | - |
| Neurocrine Clinical Site | Austin | Texas | 78754 | - |
| Neurocrine Clinical Site | DeSoto | Texas | 75115 | - |
| Neurocrine Clinical Site | Richardson | Texas | 75080 | - |
Find similar trials in Little Rock, AR
By condition
By specialty
Related Studies
- Database Registry for Neural Network Biomarkers in PsychosisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaPHASE3 · Recruiting · Gedeon Richter Plc. · Culver City, California
- Ocrelizumab for Psychosis by AutoimmunityPHASE1/PHASE2 · Recruiting · The Methodist Hospital Research Institute · Houston, Texas
- Imaging Synapses With [11C] UCB-J in the Human BrainPHASE1 · Recruiting · Davidzon, Guido, M.D. · Palo Alto, California